Urine Adiponectin Concentration in Prediction of Contrast Induced Nephropathy
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The present study is to determine the ability of urinary total adiponectin and its isoforms excretion in the prediction of contrast induced nephropathy (CIN) in the patients undergoing PCI.
| Condition |
|---|
|
Myocardial Ischemia |
| Study Type: | Observational |
| Study Design: | Observational Model: Case Control Time Perspective: Prospective |
| Official Title: | Urine Total Adiponectin and Its Isoforms Concentration in Prediction of Percutaneous Coronary Interventions Contrast Induced Nephropathy |
- increase in SCr 0.5 mg/dL(44.2 mol/L) from baseline [ Time Frame: 3 days ] [ Designated as safety issue: No ]samples will be collected at 24, 48 and 72 hours after PCI
- a 25% increase in SCr from baseline [ Time Frame: 3 days ] [ Designated as safety issue: No ]samples will be collected at 24, 48 and 72 hours after PCI.
Biospecimen Retention: Samples Without DNA
serum,urine
| Estimated Enrollment: | 400 |
| Study Start Date: | April 2010 |
| Estimated Study Completion Date: | December 2014 |
| Estimated Primary Completion Date: | April 2013 (Final data collection date for primary outcome measure) |
| Groups/Cohorts |
|---|
| Patients underging PCI |
Detailed Description:
Contrast induced nephropathy (CIN) is a severe complication after percutaneous coronary intervention (PCI). CIN is responsible for approximately genic renal insufficiency and is the third cause of hospital-acquired renal failure and the injury of endothelial of renal tubule is responsible for the CIN. However markers reliably identifying CIN in the patients undergoing PCI are rare. Adiponectin is a 30-kDa adipocyte-derived vasoactive peptide closely linked to components of the metabolic syndrome. Recent study demonstrates that the quantification of urinary adiponectin excretion appears to be an independent indicator of vascular damage potentially identifying an increased risk for vascular events. Therefore, the investigators presume that the adiponectin excretion may predict the incidence of the CIN. The present study is to determine the ability of urinary total adiponectin and its isoforms excretion in the prediction of CIN in the patients undergoing PCI.
Eligibility| Ages Eligible for Study: | 18 Years to 80 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Probability Sample |
This study enrolls a group of patients> 18 who have ST elevation myocardial infarction (STEMI) undergoing primary PCI.
Inclusion Criteria:
- All patients > 18 of age who are undergoing elective PCI and are able to give informed consent are eligible for study.
Exclusion Criteria:
- The end-stage renal failure
- The patients who are relieving dialysis
Contacts and Locations| Contact: Ling Tao, M.D Ph.D | +86-15002955798 | lingtao2006@gmail.com |
| China, Shaanxi | |
| Xijing Hospital | Recruiting |
| Xi'an, Shaanxi, China, 710032 | |
| Contact: Ling Tao, M.D Ph.D +86-15002955798 lingtao2006@gmail.com | |
| Principal Investigator: Ling Tao, M.D Ph.D | |
More Information
No publications provided
| Responsible Party: | Xijing Hospital |
| ClinicalTrials.gov Identifier: | NCT01372891 History of Changes |
| Other Study ID Numbers: | xjyy110502 |
| Study First Received: | June 10, 2011 |
| Last Updated: | November 21, 2011 |
| Health Authority: | China: Food and Drug Administration |
Keywords provided by Xijing Hospital:
|
Contrast Induced Nephropathy percutaneous coronary interventions |
Additional relevant MeSH terms:
|
Myocardial Ischemia Coronary Artery Disease Ischemia Kidney Diseases Heart Diseases Cardiovascular Diseases |
Vascular Diseases Coronary Disease Arteriosclerosis Arterial Occlusive Diseases Pathologic Processes Urologic Diseases |
ClinicalTrials.gov processed this record on May 16, 2013